VivoSeq
Other

CRC

0

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

CRC is an early-stage landscape with 0 programs across 1 company. The most active players are Mylan Pharma UK Ltd..

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Mylan Pharma UK Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed3 · 50%
Recruiting1 · 17%
Active, not recruiting1 · 17%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Safety of PET MPI Using the CRCHUM N-13 Ammonia
Recruiting·—·Phase 4·NCT03275584·20,000 enrolled
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM
Active, not recruiting·SSun Yat-sen University·Phase 2·NCT03493048·146 enrolled
MA-CRC-II-016 SHR-1811
Not yet recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07355764·80 enrolled
An Open Study to Assess the Robustness of the CRC749 Inhaler
Completed·MMylan Pharma UK Ltd.·Phase 1·NCT02474017·111 enrolled
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Completed·LLudwig-Maximilians - University of Munich·Phase 2·NCT05217069·57 enrolled
pazopanib_NCRCC,Ph2 STUDY
Completed·SSamsung Medical Center·Phase 2·NCT01538238·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)